New semaglutide pill put to the test in healthy volunteers

NCT ID NCT05784402

Completed Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested a new tablet version of the drug semaglutide in 264 healthy volunteers. The goal was to measure how much of the drug gets into the blood with the new tablet compared to the current version. Participants took different doses over 21 weeks to see which formulation provides the best drug levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide
What this could lead to: If successful, this study could help develop a more effective or convenient oral version of semaglutide, potentially improving treatment options for conditions like diabetes or obesity.
What could go wrong: This is an early Phase 1 study in healthy volunteers, not patients. It only measures drug levels in the blood, not actual treatment effects. The new formulation may not prove better or safer in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS

Contacts and locations

Locations

Altasciences Clinical Company, Inc

Montreal, Quebec, H3P 3P1, Canada
Altasciences Clinical Kansas, Inc.

Kansas City, Kansas, 66212, United States
Altasciences Clinical LA, Inc.

Cypress, California, 90630, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.